AX 202
Alternative Names: AX-202; CAL-101 - Calluna PharmaLatest Information Update: 16 Sep 2026
At a glance
- Originator Arxx Therapeutics
- Developer Calluna Pharma
- Class Anti-inflammatories; Antifibrotics; Antipsoriatics; Monoclonal antibodies
- Mechanism of Action S100 calcium-binding protein A4 inhibitors
-
Orphan Drug Status
Yes - Idiopathic pulmonary fibrosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
- Phase I Fibrosis; Inflammation; Plaque psoriasis
- Preclinical Systemic scleroderma
- Research Unspecified
Most Recent Events
- 20 May 2026 Pharmacodynamics data from a preclinical study in Idiopathic pulmonary fibrosis presented at the 122nd International Conference of the American Thoracic Society (ATS-2926)
- 31 Oct 2025 AX 202 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
- 26 Aug 2025 Pharmacodynamics data from a preclinical study in Idiopathic pulmonary fibrosis released by Calluna Pharma